PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA). Data on outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS), or acute leukemia have not been separately analyzed. PATIENTS AND METHODS: We analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acute leukemia (n = 14) who were reported to the Center for International Blood and Marrow Transplant Research from 1985 to 2007. RESULTS: Neutrophil recovery occurred in 78% and 85% of patients at days 28 and 100, respectively. Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D were 26% (95% CI, 19% to 35%) and 12% (95% CI, 7% to 19%), respectively. Survival probabilities at 1, 3, and 5 years were 64% (95% CI, 55% to 73%), 58% (95% CI, 48% to 67%), and 55% (95% CI, 45% to 64%), respectively. In univariate analysis, younger age was associated with superior 5-year survival (≤ v > 14 years: 69% [95% CI, 57% to 80%] v 39% [95% CI, 26% to 53%], respectively; P = .001). In transplantations from HLA-matched related donors (n = 82), younger patients (≤ v > 14 years: 78% [95% CI, 64% to 90%] v 34% [95% CI, 20% to 50%], respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia (67% [95% CI, 52% to 81%] v 43% [95% CI, 27% to 59%], respectively; P = .03) had superior 5-year survival. CONCLUSION: Our analysis indicates that long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is achievable. Younger patients and recipients of HLA-matched related donor transplantations who have cytogenetic abnormalities only have the best survival.
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA). Data on outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS), or acute leukemia have not been separately analyzed. PATIENTS AND METHODS: We analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acute leukemia (n = 14) who were reported to the Center for International Blood and Marrow Transplant Research from 1985 to 2007. RESULTS: Neutrophil recovery occurred in 78% and 85% of patients at days 28 and 100, respectively. Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D were 26% (95% CI, 19% to 35%) and 12% (95% CI, 7% to 19%), respectively. Survival probabilities at 1, 3, and 5 years were 64% (95% CI, 55% to 73%), 58% (95% CI, 48% to 67%), and 55% (95% CI, 45% to 64%), respectively. In univariate analysis, younger age was associated with superior 5-year survival (≤ v > 14 years: 69% [95% CI, 57% to 80%] v 39% [95% CI, 26% to 53%], respectively; P = .001). In transplantations from HLA-matched related donors (n = 82), younger patients (≤ v > 14 years: 78% [95% CI, 64% to 90%] v 34% [95% CI, 20% to 50%], respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia (67% [95% CI, 52% to 81%] v 43% [95% CI, 27% to 59%], respectively; P = .03) had superior 5-year survival. CONCLUSION: Our analysis indicates that long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is achievable. Younger patients and recipients of HLA-matched related donor transplantations who have cytogenetic abnormalities only have the best survival.
Authors: M Ayas; A Al-Jefri; M Al-Mahr; S Rifai; A Al-Seraihi; A Tbakhi; M Mustafa; A Khairy; E Moussa; A Iqbal; L Shalaby; H El-Solh Journal: Bone Marrow Transplant Date: 2005-03 Impact factor: 5.483
Authors: P A Rowlings; D Przepiorka; J P Klein; R P Gale; J R Passweg; P J Henslee-Downey; J Y Cahn; S Calderwood; A Gratwohl; G Socié; M M Abecasis; K A Sobocinski; M J Zhang; M M Horowitz Journal: Br J Haematol Date: 1997-06 Impact factor: 6.998
Authors: M Bitan; R Or; M Y Shapira; M Aker; I B Resnick; A Ackerstein; S Samuel; S Elad; S Slavin Journal: Biol Blood Marrow Transplant Date: 2006-07 Impact factor: 5.742
Authors: J Zanis-Neto; M E D Flowers; C R Medeiros; M A Bitencourt; C M Bonfim; D C Setúbal; V Funke; J Sanders; H J Deeg; H P Kiem; P Martin; W Leisenring; R Storb; R Pasquini Journal: Br J Haematol Date: 2005-07 Impact factor: 6.998
Authors: Poh-Lin Tan; John E Wagner; Arleen D Auerbach; Todd E Defor; Arne Slungaard; Margaret L Macmillan Journal: Pediatr Blood Cancer Date: 2006-05-01 Impact factor: 3.167
Authors: Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba Journal: Cancer Date: 2006-04-15 Impact factor: 6.860
Authors: Richard Mitchell; John E Wagner; Betsy Hirsch; Todd E DeFor; Heather Zierhut; Margaret L MacMillan Journal: Br J Haematol Date: 2013-10-30 Impact factor: 6.998
Authors: Margaret L MacMillan; Todd E DeFor; Jo-Anne H Young; Kathryn E Dusenbery; Bruce R Blazar; Arne Slungaard; Heather Zierhut; Daniel J Weisdorf; John E Wagner Journal: Blood Date: 2015-03-30 Impact factor: 22.113
Authors: Nicholas E Khan; Philip S Rosenberg; Harold P Lehmann; Blanche P Alter Journal: Biol Blood Marrow Transplant Date: 2015-07-14 Impact factor: 5.742
Authors: Youjin Wang; Weiyin Zhou; Blanche P Alter; Tao Wang; Stephen R Spellman; Michael Haagenson; Meredith Yeager; Stephanie J Lee; Stephen J Chanock; Sharon A Savage; Shahinaz M Gadalla Journal: Biol Blood Marrow Transplant Date: 2018-06-04 Impact factor: 5.742
Authors: R Peffault de Latour; C Peters; B Gibson; B Strahm; A Lankester; C D de Heredia; D Longoni; F Fioredda; F Locatelli; I Yaniv; J Wachowiak; J Donadieu; A Lawitschka; M Bierings; M Wlodarski; S Corbacioglu; S Bonanomi; S Samarasinghe; T Leblanc; C Dufour; J-H Dalle Journal: Bone Marrow Transplant Date: 2015-06-08 Impact factor: 5.483